Hengkang develops a targeted composition for improving mild cognitive impairment
Release time：
2020-07-24
Professor Ke Mingqing, a well-known pharmaceutical expert and chief scientist of Hengkang Pharmaceutical Co., Ltd., led by Professor Ke Mingqing, after six years of innovative scientific research, has continuously optimized and iterative formulas, and successfully developed a targeted composition for improving mild cognitive impairment (MCI) - "Yizhi Multidimensional".
The R&D team of Hengkang Pharmaceutical insists on innovating from the source, starting from the pathology, and establishing reliable drug screening models and tests. According to the characteristics of the development process of MCI, early detection and early nutritional intervention are advocated to improve MCI as soon as possible, improve cognitive function, improve memory and learning and memory functions, so as to delay or prevent AD (Alzheimer's disease). The successful application of the national patent for this scientific research achievement will surely bring new gospel to more families of MCI patients.
Hengkang Pharmaceutical has always adhered to the "intentional focus, ingenuity and quality", inherited Professor Ke's spirit of continuous innovation, and established a new benchmark in the pharmaceutical and health industry; it has always adhered to independent research and development, continuous innovation, and building core competitiveness. International R&D teams are being established in China and the United States to form a R&D system with complementary advantages and global linkage.
News
Mobile QR code
Jiangxi Hengkang Pharmaceutical Co., Ltd
TEL：18370075205
Address: No.1 Fenghuang West Avenue, Economic Development Zone, Shangrao City, Jiangxi Province
